136 related articles for article (PubMed ID: 33878040)
1. Malignant Transformation of Giant Cell Tumor of Bone 7 years After Initial Surgery: A Case Report and Literature Review.
Matsunobu T; Maekawa A; Jotatsu M; Makihara K; Hisaoka M; Iwamoto Y
JBJS Case Connect; 2021 Apr; 11(2):. PubMed ID: 33878040
[TBL] [Abstract][Full Text] [Related]
2. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
[TBL] [Abstract][Full Text] [Related]
3. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
[TBL] [Abstract][Full Text] [Related]
4. Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: a case report.
Takesako H; Osaka E; Yoshida Y; Sugitani M; Tokuhashi Y
J Med Case Rep; 2016 Mar; 10():47. PubMed ID: 26951080
[TBL] [Abstract][Full Text] [Related]
5. Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature.
Hashimoto K; Hatori M; Hosaka M; Watanabe M; Hasegawa T; Kokubun S
Tohoku J Exp Med; 2006 Feb; 208(2):157-62. PubMed ID: 16434839
[TBL] [Abstract][Full Text] [Related]
6. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
[TBL] [Abstract][Full Text] [Related]
7. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
8. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
9. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
[TBL] [Abstract][Full Text] [Related]
10. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
JBJS Case Connect; 2016; 6(3):e78. PubMed ID: 29252655
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.
Okubo T; Saito T; Mitomi H; Takagi T; Torigoe T; Suehara Y; Kaneko K; Yao T
Virchows Arch; 2013 Jul; 463(1):67-77. PubMed ID: 23748877
[TBL] [Abstract][Full Text] [Related]
12. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
13. [H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease].
Giesche JP; von Baer A; Breining T; Marienfeld R; Mellert K; Lüke J; Schultheiss M; Möller P; Barth TFE
Pathologe; 2018 Sep; 39(5):451-456. PubMed ID: 30046846
[TBL] [Abstract][Full Text] [Related]
14. Late malignant transformation of giant cell tumor of bone 41 years after primary surgery.
Kadowaki M; Yamamoto S; Uchio Y
Orthopedics; 2012 Oct; 35(10):e1566-70. PubMed ID: 23027500
[TBL] [Abstract][Full Text] [Related]
15. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
16. Symplastic/pseudoanaplastic giant cell tumor of the bone.
Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
[TBL] [Abstract][Full Text] [Related]
17. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
18. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract][Full Text] [Related]
20. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]